Investment Thesis
Senti Biosciences is a pre-revenue biotech company in severe financial distress with only ~14 months of cash runway at current burn rates. The company burns $7.5M annually while generating just $16K in revenue, supported by a critically thin equity base of $2.6M. While YoY EPS improved 77%, this reflects reduced losses on a catastrophically unprofitable business facing imminent capital constraints.
Strengths
- YoY EPS improvement of 77.3% indicates losses are moderating
- No long-term debt burden limits financial obligations
- Holds $8.9M cash reserves to fund near-term operations
Risks
- Catastrophic cash burn of $7.5M annually against only $16K revenue
- Equity base of $2.6M creates acute bankruptcy and dilution risk
- Current ratio of 1.04x indicates critically tight liquidity with minimal operational flexibility
- Approximately 14-month cash runway forces near-term capital raise or insolvency
- Liabilities of $35.7M approach total assets of $38.2M, leaving no margin for error
Key Metrics to Watch
- Quarterly operating cash burn trend and runway extension
- Clinical trial milestones and regulatory pathway progress
- Capital raise announcements and shareholder dilution impact
Financial Metrics
Revenue
16.0K
Net Income
-4.2M
EPS (Diluted)
$-0.14
Free Cash Flow
-7.7M
Total Assets
38.2M
Cash
8.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-28,850.0%
Net Margin
-26,381.3%
ROE
-164.6%
ROA
-11.0%
FCF Margin
-47,981.3%
Balance Sheet & Liquidity
Current Ratio
1.04x
Quick Ratio
1.04x
Debt/Equity
0.00x
Debt/Assets
93.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T06:57:38.981354 |
Data as of: 2026-03-31 |
Powered by Claude AI